Dr. Tay Kuang Wei, Kevin

Medical Oncology (Cancer)

Credentials	MBBS (Singapore), ABIM Int. Med (USA), ABIM Med Onc (USA), FAMS (Medical Oncology)
Language	English
Background	Dr. Kevin Tay is a consultant medical oncologist with the Oncocare Cancer Center and also a visiting consultant at the National Cancer Center Singapore. Dr. Tay received his medical degree from the National University of Singapore, School of Medicine and did his post-graduate training in Internal Medicine at the University of Hawaii and his Medical Oncology fellowship at the National Cancer Institute (NCI) in Bethesda, USA. Dr. Tay currently hold American Board certifications for the practice of Internal Medicine and Medical Oncology. During his time at the NCI, he was part of a internationally renowned research group, which included Dr. Louis Staudt, Dr. Wyndham Wilson, and Dr. Elaine Jaffe, whose main research focus was on understanding the tumor biology in aggressive lymphomas. Since returning to Singapore in 2010, Dr. Tay continued to be active in lymphoma translational research and is part of the core group at the National Cancer Center that was awarded the prestigious center grant by the National Medical Research Council of Singapore. He was also part of the research group that recently found a novel mutation in NK/T-cell lymphoma, which was featured in the Straits Times and published in Cancer Disovery Journal a few months ago. Prior to entering private practice, Dr. Tay was actively involved in both undergraduate and post-graduate training and research. He was appointed the main faculty in charge of undergraduate training and was a mentor to a number of aspiring young clinical researchers. Administratively, Dr. Tay directed all lymphoma clinical trials, served as the Principal Investigator for multiple clinical trials and set up the prospective lymphoma database during his time at the National Cancer Center Singapore. Finally, Dr. Tay continues to be active in lymphoma research both at home and internationally. He is a member of the SingHealth Institutional Review Board, designated to approve, monitor and review the research activities within SingHealth. In addition, Dr. Tay is a core member of the Singapore Lymphoma Study Group and is also actively collaborating with our Asian partners in the Asian Lymphoma Study Group.

Credentials

MBBS (Singapore), ABIM Int. Med (USA), ABIM Med Onc (USA), FAMS (Medical Oncology)

Language

English

Background

Dr. Kevin Tay is a consultant medical oncologist with the Oncocare Cancer Center and also a visiting consultant at the National Cancer Center Singapore. Dr. Tay received his medical degree from the National University of Singapore, School of Medicine and did his post-graduate training in Internal Medicine at the University of Hawaii and his Medical Oncology fellowship at the National Cancer Institute (NCI) in Bethesda, USA. Dr. Tay currently hold American Board certifications for the practice of Internal Medicine and Medical Oncology. During his time at the NCI, he was part of a internationally renowned research group, which included Dr. Louis Staudt, Dr. Wyndham Wilson, and Dr. Elaine Jaffe, whose main research focus was on understanding the tumor biology in aggressive lymphomas. Since returning to Singapore in 2010, Dr. Tay continued to be active in lymphoma translational research and is part of the core group at the National Cancer Center that was awarded the prestigious center grant by the National Medical Research Council of Singapore. He was also part of the research group that recently found a novel mutation in NK/T-cell lymphoma, which was featured in the Straits Times and published in Cancer Disovery Journal a few months ago.

Prior to entering private practice, Dr. Tay was actively involved in both undergraduate and post-graduate training and research. He was appointed the main faculty in charge of undergraduate training and was a mentor to a number of aspiring young clinical researchers. Administratively, Dr. Tay directed all lymphoma clinical trials, served as the Principal Investigator for multiple clinical trials and set up the prospective lymphoma database during his time at the National Cancer Center Singapore. Finally, Dr. Tay continues to be active in lymphoma research both at home and internationally. He is a member of the SingHealth Institutional Review Board, designated to approve, monitor and review the research activities within SingHealth. In addition, Dr. Tay is a core member of the Singapore Lymphoma Study Group and is also actively collaborating with our Asian partners in the Asian Lymphoma Study Group.